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Background: Cysteine protease inhibitors of Brugia malayi have been ascribed to be involved in parasite
development as well as to immunomodulate the host’s immune response. In Onchocerca volvulus, Onchocystatin
has been shown to induce partial protection in the mouse diffusion chamber vaccination model. In the present
study we investigated the impact of vaccination with recombinant Bm-CPI-1 and Bm-CPI-2 proteins on protection
against a subcutaneous challenge of B. malayi third stage larvae in gerbils.
Findings: Vaccination with E. coli derived recombinant B. malayi cysteine protease inhibitors (Bm-CPI-1 or -2) did
not confer protection against B. malayi L3 challenge infection in gerbils but altered the homing of a significant
number of adult worms from the lymphatics to the heart and lungs.
Conclusion: Bm-CPI vaccination-induced alteration in worm migration is consistent with our previous observations
in gerbils vaccinated with B. pahangi excretory-secretory (ES) proteins, which resulted in delayed migration of the
L3s and altered the final location of adult worms. Similar observations have also been made in dogs vaccinated with
Ancylostoma caninum proteins; an increased number of worms were recovered in the colon and not the expected
small intestine. A change in the final niche was also reported in immune versus non-immune hosts of two other gut
dwelling nematodes. Vaccination induced alteration of the parasite’s final homing might be a rare or a common
phenomenon, which unfortunately is rarely recorded. The reason for the alteration in the final niche selection by adult
nematode worms following vaccination is unknown and necessitates further investigation.
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Background
An array of filarial vaccine candidates have been tested
in various rodent models including the Brugia malayi
Mongolian gerbil system. These have been reviewed re-
cently by Morris et al. [1]. Vaccination with B. malayi irra-
diated L3 larvae conferred the highest level of protection
(56 to 91%) against subcutaneous (SC) or intraperitoneal* Correspondence: tklei1@lsu.edu
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article, unless otherwise stated.(IP) L3 challenge [1]. Apart from irradiated L3 larvae, sol-
uble extracts of microfilariae (MF) and adult worms and
some recombinant protein antigens conferred significant
protection against L3 challenged rodent animal models.
The B. malayi abundant larval transcript I (Bm-ALTI)
showed the highest levels of protection of 76% [1]. How-
ever, so far no vaccine based strategy has demonstrated
complete protection against a challenge infection in any
permissive animal model. This is likely due to the com-
plexity of filarial infections and the ability of filarial para-
sites to modulate the immune system to increase their
longevity in the mammalian host [2,3]. B. malayi, filarialtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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unresponsiveness in the peripheral T cell populations of
chronically infected patients [4,5]. Filarial parasite secreted
proteins can dampen the host immune response and
immunopathology may occur from a dysregulated re-
sponse to infection [3]. Excretory-secretory (ES) proteins
of filarial nematodes play a major role in pathogenesis,
immunodiagnosis of helminth infections and host im-
mune regulation [6,7]. The major set of proteins secreted
by filarial nematodes includes proteases, protease inhibi-
tors, venom allergen homologues, glycolytic enzymes and
lectins [8,9].
Cystatins or cysteine protease inhibitors (CPIs) have
been described across the animal and plant kingdoms.
The role of CPIs in parasitic nematodes has been attrib-
uted to essential developmental processes and to specific
interactions with the parasite’s vector and/or mammalian
hosts [10,11]. In B. malayi, three cysteine protease in-
hibitors have been characterized; these are Bm-CPI-1,
Bm-CPI-2 and Bm-CPI-3 [10,12,13]. Bm-CPI-2 has been
found in ES products and is expressed in all life stages
of B. malayi. Bm-CPI-2 acts as an immunomodulator by
blocking the activity of mammalian proteases including
the antigen-processing enzyme asparaginyl endopeptid-
ase, whereas Bm-CPI-1 and -3 are expressed in L2 and
L3 stages and have been described to have functions in
the mosquito vector necessary for transmission of the
parasite [10,13]. The amino acid sequences identified be-
tween Bm-CPI-1 and Bm-CPI-2 is 28% and the sequence
alignment is shown in Additional file 1: Figure S1.
In O. volvulus, a cysteine protease inhibitor, onchocys-
tatin (Ov7; Ov-CPI-2) was described by Lustigman et al.
[14]. The recombinant onchocystatin administered with
alum as an adjuvant was able to induce 49% reduction
in worms in an L3 challenge within diffusion chambers
[15,16]. Moreover, the levels of anti-Ov-CPI-IgG3 cyto-
philic antibodies were elevated in the putatively immune
(PI) and significantly increased with age in infected indi-
viduals implicating a potential role of Ov-CPI-2 in the
protective immunity in humans [17]. In the Litomosoides
sigmodontis-mouse model, L. sigmodontis cysteine prote-
ase inhibitor-2 (Ls-CPI-2) acts as an immunomodulator
and DNA vaccination with mutated Ls-CPI-2 along with
mutated L. sigmodontis abundant larval transcript-1
(Ls-ALT-1) conferred significant protection against an
L3 challenge leading to reduced adult worm burden and
a reduction in peripheral microfilaremia [18,19]. In the
current study, we measured the effect of vaccination
with recombinant Bm-CPI-1 or Bm-CPI-2 on protective
immunity to B. malayi infection in gerbils following a
SC challenge of L3. Our results showed that vaccination
with Bm-CPI-1 and Bm-CPI-2 when formulated in alum
did not confer protection against B. malayi infection in
Mongolian gerbils. However, it affected the final nichewhere the adult worms resided. Significantly more worms
were found in the heart and lungs and fewer worms were
found in the lymphatics of both Bm-CPI-1 and Bm-CPI-2
vaccinated animals in comparison to the adjuvant con-
trols. To the best of our knowledge, this is the first report
to demonstrate that vaccination with recombinant filarial
proteins affects filarial parasite adult worm migration and
selection of their final niche.
Methods
Expression of recombinant Bm-CPI-1 and Bm-CPI-2
DNAs encoding for the Bm-CPI-1 (GenBank accession #
AF177192) and Bm-CPI-2 (GenBank accession #AF015263)
plus a 6-histidine-tag at C-terminus were synthesized by
GenScript (Piscataway, NJ) and subsequently subcloned in-
frame into the E. coli expression vector pET41a (Novagen).
The recombinant plasmids were transformed into BL21
(DE3) (Novagen) and recombinant proteins were induced
with 0.5 mM IPTG and purified with Ni-column as de-
scribed [20]. Putative endotoxin, LPS, was removed from
the recombinant proteins using ToxinEraser endotoxin re-
moval kit following the manufacturer’s protocol (GenScript,
Piscataway, NJ).
Animals, vaccination and challenge with L3s
Eight week old male Mongolian gerbils (Meriones ungui-
culatus) purchased from Charles River Laboratories
(Wilmington, MA) were maintained on standard rodent
chow and water ad libitum. The Institutional Animal
Care and Use Committee (IACUC) at Louisiana State
University (LSU) approved the animal experimental proto-
cols. B. malayi L3s were recovered from infected Aedes
aegypti mosquitoes using the previously described Baer-
mann technique [21]. For vaccine challenge experiments,
100 B. malayi L3s in 0.5 ml of RPMI were injected sub-
cutaneously into the inguinal region of the left leg.
For proper formulation with alum, the complete binding
of Bm-CPI-1 and Bm-CPI-2 to alum (Rehydragel LV, Gen-
eral Chemical, NJ) was tested. Briefly, 2.5 μg of either re-
combinant Bm-CPI-1 or Bm-CPI-2 was mixed with 32 μg
of alum for 30 min at room temperature with shaking,
centrifuged at 2000 rpm for 5 min and then the super-
natant was run on a 12% SDS-PAGE gel. There were no
bands observed (Additional file 2: Figure S2), suggesting
that both recombinant proteins efficiently bind to alum
using this protein:adjuvant ratio.
Recombinant Bm-CPI-1 or Bm-CPI-2 was formulated
with alum using the same ratio for vaccination of gerbils
undergoing the intramuscular (IM) route of immunization.
The following groups of male gerbils (N = 10; 8 week old)
were vaccinated with: 1) 25 μg of Bm-CPI-1 absorbed to
320 μg of alum in TBS; 2) 25 μg of Bm-CPI-2 absorbed to
320 μg of alum in TBS; 3) 320 μg of alum in TBS. The first
vaccination (V1) was followed by two boosters at two week
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week before the start of each experiment and designated as
PI and 1 week after V3; designated Post-V3. Two weeks
after the third vaccination, each gerbil was challenged with
100 L3s of B. malayi subcutaneously (SC) in the medial
surface of the left leg.
Necropsy of all gerbils was performed 43 days post-
challenge. Right and left popliteal lymph nodes, right
and left renal lymph nodes, ilio-lumbar vessels, right
and left spermatic cord lymphatics, right and left sub-
inguinal and iliac lymph nodes, and right and left testes
were gently teased in PBS under a stereomicroscope. In
addition, the peritoneal cavity was washed with 1× PBS.
The viscera and the carcass were soaked for 1 hour in
1× PBS. Later the heart and lungs were gently teased in
1× PBS. Following teasing, all tissues were left to soak
for 1 hour to allow worms to emerge. The worms were
recovered, counted, and then stored in 70% ethanol and
30% glycerin for observation if needed. For the purposes
of discussion, we refer to worms collected from all
lymphatic organs, testis and spermatic cords, as worms
in the lymphatics, and worms collected from the heart
and lungs as worms in heart & lungs.
Measuring IgG response against Bm-CPI-1 and Bm-CPI-2
by ELISA
To detect gerbil-specific IgG responses we raised poly-
clonal anti-gerbil IgG antibodies in rabbits. Briefly, total
gerbil serum proteins were extracted by ammonium sul-
fate precipitation followed by the purification of the total
IgG using the Pierce protein G IgG plus orientation kit
and the manufacturer’s instructions (Thermo Scientific,
IL). Polyclonal anti-sera against gerbil IgG in rabbits was
raised under a contract with Pacific Immunology, CA.
The gerbil IgG specific antibody response induced by
vaccination with recombinant Bm-CPI-1 or Bm-CPI-2
was measured using the Rabbit Serum Antibody detec-
tion ELISA kit (Alpha Diagnostic, San Antonio, TX).
Briefly, each well of a 96 well microplate was coated at
4°C overnight with 100 μl of 1 μg/ml of the antigen (re-
combinant Bm-CPI-1 or Bm-CPI-2) in coating buffer.
The plates were washed 3 times with 200 μl of 1× wash
buffer, blocked with 200 μl of blocking solution at room
temperature for 4 hrs, then after an additional 3 washes
incubated for 2 hrs at room temperature with serial dilu-
tions of the gerbil sera collected during the course of
vaccination with either Bm-CPI-1, Bm-CPI-2 or alum
alone. Following incubation of sera, the plates were
washed 3 times with wash buffer and incubated with
100 μl of 1:5000 dilution of the rabbit anti-gerbil IgG for
1 hr. The plates were then washed 3 times with wash
buffer and incubated with 100 μl of 1:5000 dilution of
HRP-conjugated anti-rabbit IgG for 30 minutes followed
by an additional 4 washes and the addition of 100 μl ofTMB substrate for 15 minutes at room temperature. The
reaction was stopped by adding 100 μl of stop solution
(H2SO4) and the microplate was read at 450 nm using an
ELISA reader (Molecular Devices, Sunnyvale, CA).
To check if sera from the Bm-CPI-1 vaccinated gerbils
cross-reacted with the Bm-CPI-2 protein, we analysed
Bm-CPI-2 coated plates with sera from Bm-CPI-1 vacci-
nated gerbils. Likewise Bm-CPI-1 coated plates were
tested with sera from Bm-CPI-2 vaccinated gerbils.
Statistics
Differences in worm recovery were analysed by the un-
paired t test using GraphPad Prism version 4.03 for
Windows (GraphPad Software, San Diego, California).
Significance was when P ≤ 0.05.
Results
Vaccination with recombinant Bm-CPI-1 and Bm-CPI-2
did not confer protection against B. malayi infection but
altered the final niche selection by the adult worms.
Mongolian gerbils were vaccinated IM three times
with recombinant Bm-CPI-1 or Bm-CPI-2 in alum be-
fore they were challenged with 100 B. malayi L3s SC.
Forty-three days post-infection, the gerbils were eu-
thanized and necropsy was performed; adult B. malayi
worms were recovered from different tissues of gerbils
and counted. Neither vaccination with recombinant Bm-
CPI-1 nor Bm-CPI-2 resulted in significant protection
against B. malayi infection compared to the adjuvant
control group (Figure 1A). However, there was a differ-
ence in the tissue distribution of adult worms between
the antigen vaccinated groups and the adjuvant control
group. More worms were found in the heart and lungs
and fewer worms were found in the lymphatic organs of
gerbils vaccinated with recombinant Bm-CPI-1 and Bm-
CPI-2 (Figure 1B and C). The percentages of worms in
the heart and lungs of Bm-CPI-1 and Bm-CPI-2 vacci-
nated groups were 66% and 69% respectively, and the
percentage of worms in the lymphatics of Bm-CPI-1 and
Bm-CPI-2 vaccinated groups was 34% and 31%, respect-
ively. The percentage of worms in the heart and lungs or
the lymphatics in the alum control gerbils was 29% and
71%, respectively.
Gerbil IgG response to Bm-CPI-1 and Bm-CPI-2
vaccination
The end point dilution of antigen specific IgG responses
induced after three vaccinations were measured by ELISA.
High end point dilution of antigen specific IgG responses
(up to 1:2,048,000) were detected in serum from gerbils
vaccinated with Bm-CPI-1, whereas no Bm-CPI-1 specific
IgG was observed in pre-immune and alum control
serum. Antigen specific IgG end point dilution of up to
1:512,000 was detected in serum from gerbils vaccinated
AC
B
Figure 1 Vaccination with recombinant Bm-CPI-1 and Bm-CPI-2 does not confer protection against B. malayi infection in Mongolian
gerbils but affects migration of worms and habitat selection. A) Total worm count. B) Distribution of worms in heart and lungs.
C) Distribution of worms in lymphatic organs. Statistical significance was determined by unpaired t test using GraphPad Prism version 4.03,
* denotes a significant difference between vaccinated group and alum adjuvant control, P ≤ 0.05. The line represents the median value.
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antibody responses was analysed, an end point dilution of
1:512, 000 was detected when Bm-CPI-1 was tested with
serum from gerbils vaccinated with Bm-CPI-2. Similarly,
an end point dilution of 1:2,048, 000 was found when Bm-
CPI-2 coated plates were tested with serum from gerbils
vaccinated with Bm-CPI-1. The Bm-CPI-1 antibody end
point dilution was slightly higher than the Bm-CPI-2.
Discussion
Many investigators have reported protection in rodent-
Brugia models against L3 infection with a large number
of different recombinant B. malayi proteins [1]. How-
ever, there are no previous vaccination experiments
reported that tested the efficacy of Bm-CPI-1 or Bm-
CPI-2 in this model. Many studies also implicated the
potential role of antibody-mediated killing of L3 as an
effector mechanism [1]. While in our present study vaccin-
ation induced a significant antigen-specific IgG antibodyresponse against Bm-CPI-1 and Bm-CPI-2, no pro-
tection against SC L3 infection was observed. It is im-
portant to note that unlike most other reported B.
malayi-gerbil vaccination experiments, the challenge of
L3s was administered SC, which is a more similar and
natural route of infection in the human host. It also ne-
cessitates significant tissue migration by L3s and L4s in
the host and final niche selection by the adult worms
[22]. Migration and homing does not happen following
an IP challenge or by using L3s implanted in diffusion
chambers. These have been the most common routes of
challenges used in the majority of the B. malayi-gerbil
vaccination experiments reported. The current observa-
tions suggest that using our particular immunization
regimens with both Bm-CPIs were not sufficient to
block the establishment and development of B. malayi
L3s in this model. It is possible that the appropriate
protective immune responses were not generated by
this vaccination.
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CPI-2 was not protective against B. malayi infection, it
resulted in alteration of B. malayi larval migration and the
final selection of the habitat where the adult worms
resided. In the current experiment, the distribution of
worms in the heart and lungs and in the lymphatics was
shifted in such a way that more worms were recovered in
the heart and lungs than in the lymphatics in comparison
to alum control gerbils. The percentages of worms in the
heart and lungs of Bm-CPI-1 and Bm-CPI-2 vaccinated
groups was 66% and 69% respectively, and the percentage
of worms in the lymphatics of Bm-CPI-1 and Bm-CPI-2
vaccinated groups was 34% and 31% respectively. The
percentage of worms in the heart and lungs and in the
lymphatics of alum control gerbils was 29% and 71%
respectively. This is the first time out of 20 other expe-
riments performed in our laboratory using 10 other
recombinant proteins that such an outcome was ob-
served. Over 20 experiments, the average percentage of
worms recovered from the heart and lungs of alum
control groups and the antigen-vaccinated groups was
42 and 44%, respectively. In comparison, the average
percentage of worms recovered from the lymphatics
and lymph nodes of alum control groups and anti
gen-vaccinated groups was 58 and 56%, respectively
(Unpublished data). The recombinant B. malayi pro-
teins used in these experiments are homologs of O. vol-
vulus proteins reviewed elsewhere [23]. These proteins
are E. coli expressed Bm-ALT-1 (B. malayi abundant
larval transcript-1), Pichia expressed Bm-ALT-1, E. coli
expressed Bm-ALT-2, E. coli expressed Bm-FAR-1 (B.
malayi fatty acid retinol binding protein), Pichia expressed
Bm-FAR-1, E. coli expressed Bm-FAR-2, E. coli expressed
Bm-103 (B. malayi cDNA clone 103), Pichia expressed
Bm-103, E. coli expressed Bm-RAL-2 (B. malayi novel
protein reactive against larvae antiserum-2) and Pichia
expressed Bm-RAL-2. The efficacy of these proteins in
inducing a protective immunity will be discussed in sub-
sequent publications.
The reasons for this altered migration and final loca-
tion of the developed adult worms are not clear. Nor is
the reason that this is only seen following vaccination with
Bm-CPIs and not other recombinant proteins. Interest-
ingly, in previous studies using the B. pahangi-gerbil
model, we found that L3s induce an early acute inflamma-
tory response that is modulated once the parasites are
established in the lymphatics [24]. Bm-CPI-2 is a secreted
protein and was shown to be immunomodulatory [13]. It
is possible that the native Bm-CPI-2 secreted by L3s could
reduce this initial acute inflammatory response against
L3s and thus support the final residence of the worms
in the lymphatics of control animals. However, as the
vaccination with Bm-CPI-1 and/or CPI-2 induced a
strong antibody-mediated response, it is possible thatthese strong responses have blocked the function of the
native Bm-CPI-2 in the immunized gerbils. Moreover,
as antibodies to Bm-CPI-1 and -2 proteins cross-react
with each other it is possible that vaccinations with Bm-
CPI-1 have resulted in similar outcomes. As a result, a
non-modulated inflammatory response in this instance
may not have been able to kill L3s, but rather created an
unfavourable environment for the larvae in the lym-
phatics which altered their behaviour shunting them
and subsequent stages away from the lymphatics to the
heart and lungs. Our current findings are closely related
to those of a recently reported study in the B. pahangi-
gerbil model where vaccination of gerbils with B. pahangi
ES secreted during the first 24 hours of culture slowed the
early migration of the L3 challenge and subsequently also
affected the worm’s migration from the lymphatics on the
right side of the host to those on the left side [25]. Altered
homing of adult parasites following vaccination has also
been reported in dogs after vaccination with recombinant
Ancylostoma caninum tissue inhibitor of metalloprotease
(Ac-TMP) compared to dogs vaccinated with alum alone.
The vaccination with recombinant proteins resulted in the
reduction of the number of adult hookworms recovered
from the small intestine and a concomitant increase in the
number of adult hookworms recovered from the colon
[26]. The effects of host immunity on parasite behavior
have been reviewed by Damian RT [27]. The migration of
Schistosoma mansoni and Nippostrongylus brasiliensis in
mice like that of B. pahangi in gerbils was much reduced
in the immune hosts. Similar to the report on A. caninum,
the migration of larvae and adult worms of N. dubius and
the adult worms of Trichostrongylus colubriformis in
guinea pigs were significantly altered in the immune hosts.
Notably, the literature of vaccination experiments using
filarial parasite-rodent models have so far and understand-
ably focused on analyzing the reduction in worm burden
in vaccinated groups. Many if not most of these experi-
ments utilized IP or diffusion chamber L3 challenges. Fol-
lowing an IP challenge, most worms do not leave the
peritoneal cavity and have no need to migrate to find an
appropriate habitat for development. Most of the other
experiments using the SC route of challenge did not re-
port on adult worm location at necropsy. We present data
here which demonstrates the effect of vaccination with re-
combinant protein and presumably the resulting immune
response on the filarial worm’s migration and their final
selection of habitat. Alterations of a parasite’s final niche
after vaccination may be a rare phenomenon or a com-
mon phenomenon that is rarely reported. However, this
can only be demonstrated in animal models using per-
missive hosts and challenge systems that allow for more
natural migratory patterns. The reason for alteration in
the migratory pattern of Brugia adult worms following
vaccination is unclear. While speculative, Damian [27]
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occur which include: immune or inflammatory factors
present in immune animals blocking normal chemorecep-
tors, the disruption of chemotactic gradients, or the modi-
fication of the local environment. All of these may explain
in part our observations, however, why we observed this
only following vaccination with Bm-CPIs and not with
other filarial vaccine candidates is perplexing. Clearly the
understanding of this phenomenon necessitates further
investigation.
Conclusion
Vaccination with recombinant Bm-CPI-1 and Bm-CPI-2
in alum induced a significant antibody response to both
proteins and antibodies to these proteins cross-reacted
with each other. However, vaccination did not protect
gerbils against B. malayi infection in terms of worm re-
duction. Vaccination did alter the worm distribution
resulting in a decrease of adult worms in lymphatic tis-
sues and a significant increase in worm migration to the
heart and lungs. The reasons for the alteration in migra-
tion and establishment of worms in Bm-CPI-1 and Bm-
CPI-2 vaccinated gerbils are unknown. Beside the main
focus on reduction in worm burden in vaccination
experiments in the filarial parasites-animal model de-
scribed so far in literature, we have recognized a unique
and rarely reported phenomenon on the effect of vaccin-
ation on filarial worm migration and habitat selection.
Additional files
Additional file 1: Figure S1. Amino acid sequence alignment between
Bm-CPI-1(GenBank accession number: XP_001895476) and Bm-CPI-2
(AF177193_1). Sequences were aligned using CLUSTAL W and prepared for
display by BOXSHADE. The identical amino acids are shaded in black and
similar substitution in gray. Amino acids common to every sequence are
marked by asterisk below the alignment. The percentage of sequence identity
between Bm-CPI-1 and Bm-CPI-2 is shown at the end of Bm-CPI-1 sequence.
Additional file 2: Figure S2. Absorption of recombinant Bm-CPI-1 and
Bm-CPI-2 on alum. 2.5 μg of recombinant Bm-CPI-1 or BmBm-CPI-2 was
incubated with 32 μg of alum for 30 min. After centrifugation at 2000 rpm for
5 min, the supernatant was loaded on a 14-20% SDS-PAGE gel. M, molecular
weight marker; Lane 1, 2.5 μg Bm-CPI-1; Lane 2, supernatant from alum
absorbed Bm-CPI-1; Lane 3, 2.5 μg Bm-CPI-2.; Lane 4, supernatant from alum
absorbed Bm-CPI-2.
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